• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ZimVie Announces Upcoming Changes to Company's Board of Directors

    3/13/25 4:15:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care
    Get the next $ZIMV alert in real time by email

    PALM BEACH GARDENS, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced upcoming changes to the Company's Board of Directors, including: 

    • Non-Executive Chair David King will not stand for reelection as a director upon the expiration of his current term at the Company's annual meeting of shareholders on May 7, 2025.
    • President and CEO Vafa Jamali will be appointed Chairman of the Board effective as of May 7, 2025.
    • Director Vinit Asar will be appointed Lead Independent Director effective upon the commencement of Mr. Jamali's service as Chairman.

    Retirement of Mr. King

    "On behalf of ZimVie and our Board of Directors, I want to extend our deepest gratitude to David for his leadership and service as Chair during a pivotal time for the Company," said Mr. Jamali. "His experience in the healthcare and life science sectors has been instrumental in shaping ZimVie's strategic direction and positioning our Company for success."

    Appointment of Mr. Jamali as Chairman of the Board 

    "Through his leadership as President and CEO since the spinoff three years ago, Vafa has created significant shareholder value while transforming ZimVie into a pure play dental company, substantially reduced debt to improve the company's financial health and flexibility, and streamlined its operations," said Mr. King. "The Board of Directors is confident Vafa will drive even stronger value for ZimVie's stakeholders in his expanded role as Chairman."

    Appointment of Mr. Asar as Lead Independent Director

    Mr. Asar has been a member of ZimVie's Board of Directors since 2022. He currently serves as Chair of the Quality, Regulatory, and Technology Committee and as a member of each of the Audit, Corporate Governance, and Compensation Committees. Mr. Asar currently serves as the Executive Chairman of the Board of Hanger, Inc. Mr. Jamali stated, "We are honored to have Vinit serve as our Lead Independent Director. He provides valuable strategic perspective as a Board member, and I look forward to working with him in his new role."

    About ZimVie

    ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning ZimVie's expectations, plans, prospects, stakeholder value, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. For a list and description of some of such risks and uncertainties, see ZimVie's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in ZimVie's filings with the SEC. Forward-looking statements speak only as of the date they are made, and ZimVie disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.

    Media Contact Information:

    ZimVie

    Grace Flowers • [email protected]

    (561) 319-6130

    Investor Contact Information:

    Gilmartin Group LLC

    Webb Campbell • [email protected]



    Primary Logo

    Get the next $ZIMV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZIMV

    DatePrice TargetRatingAnalyst
    7/31/2025$19.00Buy → Neutral
    B. Riley Securities
    7/22/2025$19.00Underweight → Equal Weight
    Barclays
    4/10/2025$16.00Buy
    B. Riley Securities
    3/13/2025Buy → Hold
    Needham
    5/16/2024$20.00Hold → Buy
    Needham
    11/16/2023Hold
    Needham
    12/21/2022$9.00Underweight
    Barclays
    6/17/2022$20.00Neutral
    JP Morgan
    More analyst ratings

    $ZIMV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZimVie Reports Second Quarter 2025 Financial Results

    Recently entered into definitive agreement to be acquired by ARCHIMED for $19.00 in cash per shareNet Sales from Continuing Operations of $116.7 millionNet Loss from Continuing Operations of $(3.8) million; Net Loss margin of (3.3)% Adjusted EBITDA[1] from Continuing Operations of $17.5 million; Adjusted EBITDA[1] margin of 15.0%GAAP diluted EPS from Continuing Operations of $(0.14) and adjusted diluted EPS[1] from Continuing Operations of $0.26 PALM BEACH GARDENS, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today reported financial results for the quarter ended June 30, 2025. "Our results this quarter ref

    7/30/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025

    PALM BEACH GARDENS, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025. On July 21, 2025, ZimVie issued a press release announcing ZimVie's entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED ("ARCHIMED") for $19.00 in cash per share. A copy of that press release is accessible by visiting the "Investor Relations" section of ZimVie's website. The transaction is expected to close by year-end 2025, su

    7/25/25 8:00:00 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie Announces Exclusive Distribution Agreement with Osstem Implant to Expand Premium Dental Implant Offering in China

    PALM BEACH GARDENS, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced a strategic distribution agreement with Osstem Implant Co., Ltd. ("Osstem Implant"), a leading dental solutions provider specializing in high-quality implants and integrated dental technologies globally. The agreement expands ZimVie's global presence to further penetrate the large, growing Chinese implant market—estimated at greater than 10 million units annually1—and enhance customer access to its innovative implant portfolio. Osstem Implant is the market-leading provider of dental implants in China, with broad, established dis

    7/23/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    SEC Filings

    View All

    SEC Form PREM14A filed by ZimVie Inc.

    PREM14A - ZimVie Inc. (0001876588) (Filer)

    8/15/25 5:02:32 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.

    SCHEDULE 13G/A - ZimVie Inc. (0001876588) (Subject)

    8/14/25 9:11:30 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by ZimVie Inc.

    DEFA14A - ZimVie Inc. (0001876588) (Filer)

    7/30/25 4:15:04 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Kanaglekar Indraneel covered exercise/tax liability with 145 shares, decreasing direct ownership by 0.23% to 62,851 units (SEC Form 4)

    4 - ZimVie Inc. (0001876588) (Issuer)

    7/3/25 4:17:15 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Kuntz Richard

    4 - ZimVie Inc. (0001876588) (Issuer)

    7/2/25 4:36:01 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Chief Accounting Officer Schneider Sandra converted options into 11,127 shares and covered exercise/tax liability with 2,710 shares, increasing direct ownership by 26% to 40,794 units (SEC Form 4)

    4 - ZimVie Inc. (0001876588) (Issuer)

    5/19/25 4:18:13 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ZimVie downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded ZimVie from Buy to Neutral and set a new price target of $19.00

    7/31/25 7:17:57 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie upgraded by Barclays with a new price target

    Barclays upgraded ZimVie from Underweight to Equal Weight and set a new price target of $19.00

    7/22/25 10:21:16 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on ZimVie with a new price target

    B. Riley Securities initiated coverage of ZimVie with a rating of Buy and set a new price target of $16.00

    4/10/25 12:44:28 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Leadership Updates

    Live Leadership Updates

    View All

    ZimVie Announces Upcoming Changes to Company's Board of Directors

    PALM BEACH GARDENS, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced upcoming changes to the Company's Board of Directors, including:  Non-Executive Chair David King will not stand for reelection as a director upon the expiration of his current term at the Company's annual meeting of shareholders on May 7, 2025.President and CEO Vafa Jamali will be appointed Chairman of the Board effective as of May 7, 2025.Director Vinit Asar will be appointed Lead Independent Director effective upon the commencement of Mr. Jamali's service as Chairman. Retirement of Mr. King "On behalf of ZimVie and our Boar

    3/13/25 4:15:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Veradigm Announces Board Expansion and Changes

    Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

    2/20/25 4:02:00 PM ET
    $MDRX
    $OCX
    $ZIMV
    EDP Services
    Technology
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ZIMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ZimVie Inc.

    SC 13G - ZimVie Inc. (0001876588) (Subject)

    11/14/24 4:11:11 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

    SC 13G/A - ZimVie Inc. (0001876588) (Subject)

    11/14/24 10:58:06 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

    SC 13G/A - ZimVie Inc. (0001876588) (Subject)

    10/4/24 1:02:25 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Financials

    Live finance-specific insights

    View All

    ZimVie Reports Second Quarter 2025 Financial Results

    Recently entered into definitive agreement to be acquired by ARCHIMED for $19.00 in cash per shareNet Sales from Continuing Operations of $116.7 millionNet Loss from Continuing Operations of $(3.8) million; Net Loss margin of (3.3)% Adjusted EBITDA[1] from Continuing Operations of $17.5 million; Adjusted EBITDA[1] margin of 15.0%GAAP diluted EPS from Continuing Operations of $(0.14) and adjusted diluted EPS[1] from Continuing Operations of $0.26 PALM BEACH GARDENS, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today reported financial results for the quarter ended June 30, 2025. "Our results this quarter ref

    7/30/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025

    PALM BEACH GARDENS, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025. On July 21, 2025, ZimVie issued a press release announcing ZimVie's entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED ("ARCHIMED") for $19.00 in cash per share. A copy of that press release is accessible by visiting the "Investor Relations" section of ZimVie's website. The transaction is expected to close by year-end 2025, su

    7/25/25 8:00:00 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie Reports First Quarter 2025 Financial Results

    Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

    5/8/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care